



ASX ANNOUNCEMENT

18 MARCH 2025

Entitlement Offer to raise approximately \$3.2 million

Key Points

- Non-renounceable entitlement offer to eligible shareholders to raise approximately \$3.2 million.
- Offer price of \$0.005 per new share on a 2 for 5 basis.
- 1 new option for every new share issued with an exercise price of \$0.008 and expiry date of 19 December 2025.
- Following successful completion, funds will primarily be used for continued development of Chimeric's CHM CDH17 Phase 1/2 clinical trial.

Melbourne, Australia, 18 March 2025: Chimeric Therapeutics Limited (ASX:CHM) (**Chimeric or Company**) is pleased to announce that it intends to conduct an equity raising via a pro-rata non renounceable entitlement offer to eligible shareholders of fully paid ordinary shares in Chimeric to raise approximately \$3.2 million (**Entitlement Offer**).

The offer price for the Entitlement Offer will be \$0.005 per share (**Offer Price**). The Offer Price represents:

- a 16.7% discount to the theoretical ex-rights price (**TERP**);¹
- a 23.1% discount to the last closing price of \$0.0065 (26 February 2025); and
- a 28.6% discount to the 5-day volume weighted average price (**VWAP**) of \$0.007.

Under the Entitlement Offer, eligible shareholders will be able to subscribe for 2 new fully paid ordinary shares in Chimeric (**New Shares**), and 1 new attaching option for every New Share issued (**New Option**), for every 5 existing ordinary shares held at 7pm (AEDT) on Friday, 21 March 2025 (**Record Date**) at the Offer Price (**Entitlement**).

¹ The theoretical ex-rights price of \$0.006 is calculated using Chimeric's closing price on 17 March 2025, assuming proceeds from the Entitlement Offer of \$3.2 million. TERP is the theoretical price at which shares should trade immediately after the ex-date for the Entitlement Offer assuming 100% take-up of the Entitlement Offer. TERP is a theoretical calculation only and the actual price at which shares trade immediately after the ex-date for the Entitlement Offer will depend on many factors and may not be equal to the TERP.



Approximately 638 million New Shares will be issued as part of the Entitlement Offer. New Shares issued under the Entitlement Offer will rank equally with existing shares.

The New Options will have an exercise price of \$0.008 per New Option and an expiry date of 19 December 2025².

The Entitlement Offer has been jointly managed by PAC Partners Securities Pty Ltd and Taylor Collison Limited, who will be issued 25 million Adviser Options under the Offer on account of professional services provided to the Company.

Use of Funds

Funds raised from the Entitlement Offer are intended to be applied to:

- CHM CDH17 CAR-T Program: CHM is continuing to dose patients in this Phase 1/2 trial in patients with neuroendocrine tumours, colorectal cancer and gastric cancer. Four patients have been dosed with five successful manufacturing runs to date.
- CHM CORE-NK: In partnership with Case Western University, Chimeric has commenced a novel Phase 1B clinical trial with its CORE-NK platform. The trial is the first-ever trial to assess NK cells in combination with Vactosertib in patients with advanced colorectal and blood cancers. In addition, CHM in partnership with MD Anderson Cancer Centre, is evaluating the synergy of NK cell therapy in combination with the current standard of care for blood cancer, Azacitidine and Venetoclax (aza/ven) in the frontline setting.
- General working capital and costs of the capital raising. ongoing working capital and the costs of the Entitlement Offer.

Entitlements

Eligible shareholders can choose to take up all, part or none of their Entitlement.

The Entitlements are non-renounceable and will not be tradeable on ASX or otherwise transferable.

Shareholders who do not take up their Entitlements will not receive any value for those Entitlements that they do not take up. Shareholders who are not eligible to receive Entitlements will not receive any value for the Entitlements they would have received had they been eligible.

The Entitlement Offer will include a top up facility under which eligible shareholders who take up their full Entitlement will be invited to apply for additional New Shares (and attaching New

² Eligible shareholders must, at the issuance date of New Options, hold at least the number of New Shares they subscribed for under the Entitlement Offer.



Options) in the Entitlement Offer from a pool of those not taken up by other eligible shareholders. There is no guarantee that applicants under this top up facility will receive all or any of the New Shares they apply for under the facility.

Chimeric reserves the right to place any shortfall under the Entitlement Offer within three months after the Closing Date.

Chimeric will notify shareholders as to whether they are eligible to participate in the Entitlement Offer. Further details about the Entitlement Offer will be set out in the Entitlement Offer prospectus (**Prospectus**), which will be dispatched to shareholders with a personalised entitlement and acceptance form.

Chimeric's CEO Dr Rebecca McQualter said: "I would like to thank our shareholders for their ongoing support to continue our innovative work to bring cell therapy to patients in need."

Key dates³

Event	Date
Announcement of the Offer	18 March 2025
Prospectus date	18 March 2025
Ex date	20 March 2025
Record Date for Offer (7.00pm, Sydney time)	21 March 2025
Prospectus and Entitlement and Acceptance Form despatched	25 March 2025
Offer opens	25 March 2025
Offer closes (5.00pm, Sydney time) (Closing Date)	8 April 2025
New Shares quoted on a deferred settlement basis	9 April 2025
Announcement of results of the Offer	10 April 2025
Allotment of New Shares and New Options issued under the Offer	15 April 2025
Despatch of holding statements for New Shares and New Options issued under the Offer	15 April 2025

³All dates are indicative only and subject to change. Chimeric reserves the right to withdraw or vary the timetable without notice.



About Chimeric

Chimeric, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR-T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR-T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR-T was published by Dr. Hua and colleagues in 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR-T therapy developed for the treatment of patients with solid tumours. CLTX CAR-T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Executive Chairman Paul Hopper.

For further information, please contact:

If you have questions about the Entitlement Offer, please contact the share registry, Boardroom Pty Ltd on 1300 737 760 (inside Australia) or +61 2 9290 9600 (outside Australia).

Important information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to in this document have not been and will



not be registered under the United States Securities Act of 1933 (the 'US Securities Act'), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.

This document may not be distributed or released in the United States.

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. Chimeric does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.